Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group

Trial Profile

Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms NEMO
  • Most Recent Events

    • 25 Apr 2018 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
    • 25 Apr 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2019.
    • 25 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top